

1 **SARS-CoV-2 viral replication persists in the human lung for several weeks after**  
2 **symptom onset**

3

4 **Running title:** Persistence of SARS-CoV-2 in the human lung.

5

6 Tomasicchio M<sup>1,2</sup>, Jaumdally S<sup>1,2</sup>, Pooran A<sup>1,2</sup>, Esmail A<sup>1,2</sup>, Wilson L<sup>1,2</sup>, Kotze A<sup>1,2</sup>, Semple  
7 L<sup>1,2</sup>, Meier S<sup>1,2</sup>, Pillay K<sup>5</sup>, Roberts R<sup>5</sup>, Kriel R<sup>5</sup>, Meldau R<sup>1,2</sup>, Oelofse S<sup>1,2</sup>, Mandiwala C<sup>1,2</sup>,  
8 Burns J<sup>1,2</sup>, Londt R<sup>1,2</sup>, Davids M<sup>1,2</sup>, van der Merwe<sup>1,2</sup> C, Roomaney A<sup>1,2</sup>, Kühn L<sup>1,2</sup>, Perumal  
9 T<sup>1,2</sup>, Scott A.J<sup>1,2</sup>, Hale M.J<sup>6</sup>, Baillie V<sup>7</sup>, Mahtab S<sup>7</sup>, Williamson C<sup>8</sup>, Joseph R<sup>8</sup>, Sigal A<sup>9</sup>,  
10 Joubert I<sup>10</sup>, Piercy J<sup>10</sup>, Thomson D<sup>10</sup>, Fredericks DL<sup>10</sup>, Miller MGA<sup>10</sup>, Nunes M.C<sup>7</sup>, Madhi  
11 S.A<sup>7</sup>, Dheda K<sup>1,2,3,4</sup>.

12

13 **Affiliations:**

14 <sup>1</sup> Centre for Lung Infection and Immunity, Division of Pulmonology, Department of  
15 Medicine, University of Cape Town and UCT Lung Institute, FCape Town, South Africa.

16 <sup>2</sup> South African MRC Centre for the Study of Antimicrobial Resistance, University of Cape  
17 Town, Cape Town, South Africa.

18 <sup>3</sup> Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape  
19 Town, South Africa.

20 <sup>4</sup> Faculty of Infectious and Tropical Diseases, Department of Immunology and Infection,  
21 London School of Hygiene & Tropical Medicine, London, UK.

22 <sup>5</sup> Division of Anatomical Pathology, Department of Pathology, University of Cape Town,  
23 Cape Town, South Africa

24 <sup>6</sup> Division of Anatomical Pathology, Faculty of Health Sciences, University of the  
25 Witwatersrand.

26 <sup>7</sup> South African Medical Research Council, Vaccines and Infectious Diseases Analytics  
27 Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg,  
28 South Africa; Department of Science and Technology/National Research Foundation South  
29 African Research Chair Initiative in Vaccine Preventable Diseases, Faculty of Health  
30 Sciences, University of the Witwatersrand, Johannesburg, South Africa.

31 <sup>8</sup> Division of Medical Virology, Institute of Infectious Disease and Molecular Medicine,  
32 University of Cape Town, Cape Town, South Africa.

33 <sup>9</sup> Africa Health Research Institute, Durban, South Africa.

34 <sup>10</sup> Division of Critical Care, Department of Anaesthesia and Perioperative Medicine,  
35 University of Cape Town, South Africa.

36

37 Correspondence: Keertan Dheda, Centre for Lung Infection and Immunity, Division of  
38 Pulmonology and UCT Lung Institute, Dept of Medicine, University of Cape Town, South  
39 Africa. E-mail: keertan.dheda@uct.ac.za

40

41

42 **ABSTRACT**

43 **Rationale:** In the upper respiratory tract replicating (culturable) SARS-CoV-2 is recoverable  
44 for ~ 4 to 8 days after symptom onset, however, there is paucity of data about the frequency  
45 or duration of replicating virus in the lower respiratory tract (i.e. the human lung).

46 **Objectives:** We undertook lung tissue sampling (needle biopsy), shortly after death, in 42  
47 mechanically ventilated decedents during the Beta and Delta waves. An independent group of  
48 18 ambulatory patients served as a control group.

49 **Methods:** Lung biopsy cores from decedents underwent viral culture, histopathological  
50 analysis, electron microscopy, transcriptomic profiling and immunohistochemistry.

51 **Results:** 38% (16/42) of mechanically ventilated decedents had culturable virus in the lung  
52 for a median of 15 days (persisting for up to 4 weeks) after symptom onset. Lung viral culture  
53 positivity was not associated with comorbidities or steroid use. Delta but not Beta variant lung  
54 culture positivity was associated with accelerated death and secondary bacterial infection  
55 ( $p < 0.05$ ). Nasopharyngeal culture was negative in 23.1% (6/26) of decedents despite lung  
56 culture positivity. This, hitherto, undescribed bio-phenotype of lung-specific persisting viral  
57 replication was associated with an enhanced transcriptomic pulmonary pro-inflammatory  
58 response but with concurrent viral culture positivity.

59 **Conclusions:** Concurrent, rather than sequential active viral replication continues to drive a  
60 heightened pro-inflammatory response in the human lung beyond the second week of illness  
61 and was associated with variant-specific increased mortality and morbidity. These findings  
62 have potential implications for the design of interventional strategies and clinical management  
63 of patients with severe COVID-19 disease.

64 243 words

65 **Keywords:** COVID-19, SARS-CoV-2, virus replication, mechanically ventilated patients,  
66 upper respiratory tract, immunology

67 **At a Glance Commentary**

68 **Scientific Knowledge on the Subject:**

69 Investigations to understand SARS-CoV-2 viral shedding (determined by PCR or antigen  
70 testing) have extensively focused on samples from the upper respiratory tract. The widely  
71 accepted view is that acute severe SARS-CoV-2 infection is characterised by a viral  
72 replicative phase in the first week of symptomatic illness followed by a pro-inflammatory  
73 immunopathologic phase peaking in the second and third weeks of illness. However, it  
74 remains unclear whether detection of SARS-CoV-2 beyond 2 weeks after symptom onset in  
75 published studies represent active replication competent virus because it may represent  
76 residual genomic or antigenic material in the tissue.

77

78 **What This Study Adds to the Field:**

79 We have identified a, hitherto, undescribed bio-phenotype of acute severe COVID-19  
80 characterised by persisting viral replication in the lung for up to 4 weeks after symptom  
81 onset. ~40% of acute severe COVID-19 intensive care unit (ICU) decedents (n=42) had  
82 nasopharyngeal swab culture positivity at ~2 weeks post-symptom onset versus only ~5% in a  
83 group of ambulatory control patients (n=18). There was compartment-specific (nasopharynx  
84 versus lung) discordance. The phenotype of lung-specific persisting viral replication was  
85 associated with variant-specific accelerated death, an exaggerated inflammatory response, and  
86 attenuated T-cell immunity in the lung (based on histopathological and transcriptomic  
87 studies). This challenges the traditional view that viral replication occurs during the first 5 to  
88 10 days of illness, which is followed by an effector or hyperinflammatory phase. This is the  
89 first study, to our knowledge, to systematically culture virus from the human lung and map  
90 out its related clinical determinants, and which describes the human lung transcriptomic  
91 profile of culture-positive versus culture-negative patients with severe COVID-19 disease.

92 **Introduction.**

93 Coronavirus disease-19 (COVID-19) caused by the Severe Acute Respiratory Syndrome  
94 Coronavirus-2 (SARS-CoV-2) has been the foremost killer globally over the last 3 years.  
95 Case fatality risk in hospitalised patients, and particularly in mechanically ventilated patients,  
96 during the Beta and Delta waves was particularly high [ $\sim$ 50%-70%; (1)]. Even with the  
97 Omicron-related variants, case fatality risk remains significant in the elderly and  
98 immunocompromised persons, and in several countries including the UK, Italy, France,  
99 Brazil, and prominently in China where there is now an ongoing epidemic of severe COVID-  
100 19 disease (2-10). Better therapeutic interventions are needed. However, despite considerable  
101 research, the pathogenesis of severe COVID-19, relative to viral kinetics, remains  
102 incompletely understood.

103

104 SARS-CoV-2 detection (ascertained through PCR positivity or antigen detection) can persist  
105 for several weeks from symptom onset (11). Post-mortem studies have shown persistence of  
106 SARS-CoV-2 in tissues detected by PCR and immunohistochemistry for up to several weeks  
107 after symptom onset (12, 13). However, detection of SARS-CoV-2 in these studies may not  
108 represent replication competent virus (detectable only by viral culture) but residual genomic  
109 or antigenic material in the tissues. Shedding of replicating virus confirmed through serial  
110 viral culture (i.e. *in vitro* replication in human cell lines) from the upper respiratory tract  
111 (URT) has been shown to persist for only  $\sim$ 2 to 8 days after symptom onset (11, 14-23). These  
112 findings have been confirmed in human lung challenge studies with viable pathogen where  
113 virus was cultured from the URT until a median of 4 days (and a maximum of 10 days) from  
114 symptom onset (24). However, hardly anything is known about the compartment-specific  
115 duration of actively replicating virus in the lower respiratory tract (LRT), particularly in acute  
116 severely ill hospitalised patients undergoing mechanical ventilation. We hypothesised that

117 there is compartment-specific uncoupling of viral replication in severe COVID-19 i.e.  
118 replicating virus can persist in the LRT beyond 10 days from symptoms onset, independent of  
119 its persistence in the URT, and this persistence may be associated with an altered pulmonary  
120 immunity.

121

122

### 123 **Methods.**

#### 124 **Patients.**

125 The decedents (n=42) were recruited from Chris Hani Baragwanath Academic Hospital,  
126 Johannesburg, South Africa (n=18; Beta group) and Groote Schuur Hospital, Cape Town,  
127 South Africa (n=24; Delta group). Figure 1A outlines an overview of the study plan.  
128 Ambulatory controls (n=18) were recruited at diagnosis (baseline; ~5 days from symptom  
129 onset), 7 days and 14 days post diagnosis. Minimally invasive tissue samples (MITS) and  
130 nasopharyngeal swabs from decedents (n=42) in the Beta and Delta waves (Figure 1B) were  
131 taken immediately after death. In addition, heart, liver, kidney, and adipose tissue samples  
132 were also taken from the Delta variant decedent cohort only. Ethical approval was obtained  
133 from the Human Research Ethics Committee (HREC) of the University of Cape Town  
134 (HREC approval number 866/2020) and University of Witwatersrand (HREC approval  
135 number M200313). Biosafety approvals were obtained from the Faculty Biosafety Committee  
136 of the University of Cape Town (IBC008-2021).

137

#### 138 **Viral culture.**

139 To establish the *in vitro* viral culture model, a SARS-CoV-2 viral stock was used to infect the  
140 human lung carcinoma cell line, H1299 ACE2, in a BSL3 laboratory and infection was  
141 confirmed by light microscopy (as assessed by cytopathic effects of the virus on the cell line)

142 and confocal microscopy (Figure S1A and B). Serial dilutions of the viral stock were used to  
143 establish the limit of detection of the PCR assay at  $1 \times 10^1$  copies/ml (Figure S1C). Viral  
144 culture was performed on the nasopharyngeal swab and lung biopsy samples as indicated in  
145 the study overview (Figure 1) and detailed in the online supplement. Viral culture result  
146 reproducibility was good (see online supplement).

147

#### 148 **Multiplex PCR to detect secondary bacterial infections.**

149 The lung biopsy cores, stored in universal transport medium, were briefly homogenised and  
150 200µl of the supernatant was applied to the BioFire® FilmArray® Pneumonia panel  
151 (Biomérieux, South Africa). The panel was run using protocol BAL v3.3 according to the  
152 manufacturer's instructions, thus generating RT-PCR readouts for 33 bacterial and viral  
153 pathogens. Bronchopneumonia was defined as histological evidence of a neutrophilic alveolar  
154 infiltration together with the detection of bacterial genomic material in the biopsy cores.

155

#### 156 **Immunohistochemistry.**

157 Immunohistochemical staining was performed using the Roche Ventana Automated platform  
158 (Ventana XT autostainer) as indicated by the manufacturer. Tissue sections were prepared,  
159 stained, and viewed using standard techniques (25). Antibodies included anti-CD3 (2GV6),  
160 anti-CD4 (SP35), anti-CD8 (SP57) and anti-CD68 (KP-1) (Roche USA).

161

#### 162 **Haematoxylin & eosin (H&E) staining and transmission electron microscopy (TEM).**

163 H&E staining and TEM were performed according to standard procedures (25). H&E-stained  
164 slides were viewed using an Olympus BX43 microscope. TEM tissue sections were viewed  
165 using a Carl Zeiss EM109 microscope.

166

167 **SARS-CoV-2 whole genome sequencing.**

168 Total SARS-CoV-2 RNA was extracted from lung biopsy samples and whole genome  
169 sequencing was performed. The generated reads were analysed with the Exatype  
170 (<https://exatype.com>) software to identify minor and major variants. The assembled consensus  
171 sequences were analysed using Nextclade Web (<https://clades.nextstrain.org>) for further  
172 quality control and clade assignment.

173

174 **RNAseq.**

175 Total RNA was extracted from lung biopsy samples from the Delta group, sequenced and  
176 mapped consecutively to the human and COVID reference genomes using the Spliced  
177 Transcripts Alignment to a Reference (STAR) software [version 2.7.7a, (26)]. A differential  
178 expression (DE) analysis was performed on the generated raw read count file with the edgeR  
179 (Version 3.38.4) R package (27). The DE results were ranked by fold change and the gseGO  
180 function, from the clusterProfiler R clusterProfiler [Version 4.0, (28)] R package was used to  
181 perform a gene set enrichment analysis (GSEA) for the Gene Ontology Biological Process  
182 pathways. Pathways with an FDR <0.05 were considered significant.

183

184 **Confocal microscopy.**

185 The H1299 ACE2 cells were plated, infected with SARS-CoV-2 and allowed to adhere to  
186 coverslips slides overnight at 37°C. The next day the cells were stained with or without anti-  
187 SARS-CoV-2 S1 spike protein (ThermoFisher, USA) and the slides were mounted in Mowiol  
188 (Calbiochem, USA) containing n-propyl gallate (Sigma-Aldrich, Germany) as an anti-fading  
189 agent. Confocal microscopy was performed with a Zeiss Axiovert 200M LSM510 Meta NLO  
190 Confocal Microscope.

191



192 **Sample size calculation and statistical analysis.**

193 We hypothesised that we would detect lung culture positivity at 14 days post-symptom onset  
194 in ~33% of decedents. A sample size of ~40 participants would allow us to ascertain that level  
195 of positivity with a 15% margin of error using 95% confidence and 80% power (OpenEpi,  
196 Version 3, opensource calculator).

197

198 The Fisher Exact test was employed for categorical variables and for continuous variables,  
199 Mann-Whitney test was used for non-parametrically distributed data between the culture-  
200 negative and culture-positive groups (Stata version 17 or GraphPad, Version 9.4.1). A p-value  
201 of  $< 0.05$  was considered significant for all statistical analyses.

202

203 The multivariable analysis was performed in R by fitting a binomial Generalized Linear  
204 Model (GLM) to assess the association between steroid use and the presence of secondary  
205 bacterial infection on culture status. The tidymodels (version, 1.0.0) R package was used to  
206 perform predictive modelling using the glm binomial classification algorithm. To account for  
207 the small sample size, 1000 bootstraps were performed for each analysis.

208

209

210 **Results**

211 **Demographics and clinical characteristics of the decedents.**

212 The demographics of patients enrolled in the study are shown in Table S1. The median age of  
213 the patients was 53 years with 48% being males (20/42). 40.5% (17/42) had a secondary  
214 bacterial infection and 11% (4/38) had bacterial bronchopneumonia (microbiologically and  
215 histopathological confirmed). The median time from onset of symptoms to death, ICU

216 admission to death and high flow oxygen admission to death was 17 (IQR; 9-22), 5 (2-12) and  
217 11 (6-15) days, respectively.

218

219 **SARS-CoV-2 replicating persistence in the human lung of mechanically ventilated**  
220 **decedents.**

221 We first ascertained the frequency and duration of replicating virus in lung tissue (which to  
222 our knowledge has not been previously undertaken). Culturable virus in the lung was present  
223 in 38.1% (16/42; Figure 2A) of mechanically ventilated ICU decedents, at a median of 15  
224 days (and up ~4 weeks; Figure S2) from symptom onset to sampling/death (Figure 3A). As  
225 expected, 56% (10/18) of a prospectively recruited control group of ambulatory patients had  
226 culturable virus, using nasopharyngeal swab samples, at day 5 from symptom onset (Figure  
227 2B). In the same group of patients after 12- and 19- days after symptom onset, only 5.5%  
228 (1/18) and 0% (0/18), respectively, had culturable virus from their nasopharyngeal swab  
229 (Figure 2B). By contrast, 38% of nasopharyngeal swabs from the mechanically ventilated  
230 ICU descendants had culturable virus (Figure 2B), at a median of 13 days from symptom  
231 onset to sampling/death (Figure S3B). Additionally, SARS-CoV-2 could be detected by PCR  
232 in multiple organs in lung culture-positive decedents in the Delta cohort (biopsies other than  
233 the lung were not performed in the Beta cohort) suggesting widespread multi-organ viral  
234 dissemination (Figure 2C). SARS-CoV-2 was also detected in adipose tissue of culture-  
235 positive decedents (hitherto undescribed). Clinical characteristics, such as, age and  
236 comorbidities were similar in the lung culture-positive versus culture-negative groups (Table  
237 S1). We found no association between viral genetic variant and the phenotype of replicating  
238 viral persistence (although this might have been a factor of the limited sample size; Table S5).

239

240

241 **Time to death in the Delta and Beta groups and predictors of lung culture positivity.**

242 Next, we evaluated variant-specific relationships to clinical outcomes. Mechanically  
243 ventilated patients who were SARS-CoV-2 lung culture-positive in the Delta, but not the Beta  
244 group, had accelerated death (i.e. shorter duration from symptom onset to death; Figure 3C  
245 versus 3B;  $p=0.004$ ), and a higher proportion of lung-specific secondary bacterial infection  
246 (Figure 3F versus 3E;  $p=0.032$ ) compared to culture-negative decedents. Similarly, to the lung  
247 culture data, the nasopharyngeal swab culture-positive Delta, but not the Beta group, had  
248 accelerated death (Figure S3D versus S3C;  $p=0.026$ ).

249 The bacterial species identified from the lung biopsies of both the Beta and Delta groups  
250 included *Streptococcus*, *Staphylococcus*, *Haemophilus*, *Acinetobacter*, *Proteus* spp,  
251 *Escherichia*, *Klebsiella*, *Enterobacter* and *Serratia* (Table S4). Overall, both groups were  
252 infected with one or more bacteria that were sensitive or resistant to  $\beta$ -lactams and/or  
253 carbapenems (Table S4). Key clinical and demographic characteristics such as differences in  
254 co-morbidities (age, obesity, diabetes, HIV positivity etc; Table S1) associated as drivers of  
255 severe COVID-19 disease and poor prognosis, could not explain these observations, despite  
256 the lower population-level vaccination and pre-existing COVID-19 exposure rates in the Beta  
257 cohort. Steroid usage was similar in the culture-positive and culture-negative groups (Table  
258 S1) and there was no significant ( $p>0.05$ ) association between steroid use and the presence of  
259 secondary bacterial infection in a multivariable analysis.

260

261 Next, we interrogated whether nasopharyngeal PCR characteristics (Ct value), either at  
262 admission or close to death, could identify the phenotype of lung replicating viral persistence.  
263 However, nasopharyngeal Ct neither at admission, nor at the time of death was associated  
264 with lung culture positivity (Figure 3G). This suggests that the kinetics of viral replication  
265 was different in the upper and the lower respiratory tract.

266 **Lung immunity and histology of the culture-negative versus culture-positive groups.**

267 We then ascertained whether the phenotype of replicating viral persistence was associated  
268 with attenuated or modulated lung immunity in the Delta decedents (transcriptomic and flow  
269 cytometric studies were only carried out in Cape Town, i.e the Delta decedents, due to  
270 location-specific availability of assays and limited Beta group biopsy cores that had been used  
271 for unrelated studies). Immunohistochemical staining indicated that there was significantly  
272 less infiltration of CD3+ T-cells, specifically CD8+ T-cells in the alveoli and interstitium of  
273 the SARS-CoV-2 culture-positive compared with the culture-negative individuals in the Delta  
274 decedents (Figure 4A and B).

275

276 The typical histological features of severe COVID-19 (e.g. diffuse alveolar damage and  
277 microvascular thrombosis) were similar in the SARS-CoV-2 culture-positive and the culture-  
278 negative phenotype suggesting that these events occurred in the early rather than the  
279 persistent viral replication phase (Figure 4C, D and S4; Table S2, S3). Interestingly, we  
280 observed that some features of leucocyte hyperactivation (i.e., hemophagocytic syndrome)  
281 were more common in the SARS-CoV-2 culture-negative versus the culture-positive group,  
282 potentially in keeping with an aberrant immune response characterised by a lack of immune  
283 regulation, as outlined above (Figure 4C and 4D;  $p=0.013$ ).

284

285 The transcriptional analysis of post-mortem lung tissue identified 630 up- and 885  
286 downregulated genes at an uncorrected  $p$ -value  $\leq 0.05$  when comparing the culture-positive  
287 versus negative-groups (Figure S5). After adjustment for multiple testing, the same  
288 comparison identified a total of 11 up- and 4 down-regulated genes ( $FDR < 0.05$ ; specific  
289 genes discussed further in the online supplement; Figure S6).

290

291 The GSEA performed using the full list of differentially expressed genes ranked by fold-  
292 change, identified activated pathways that were associated with a proinflammatory response  
293 related to cytokine signalling, neutrophil and monocyte chemotaxis/recruitment, and viral  
294 entry/defence, all of which are implicated in COVID-19-related hypercytokinaemia (29)  
295 (Figure 5, S5, S6 and S7, Table S6 and S7A). Significantly repressed pathways were  
296 generally associated with body homeostasis (Figure 5A and B). There was also in tandem  
297 upregulation of Th1 and Th17 signalling pathways (Table S7B) but to a substantially lesser  
298 extent than that of innate cellular and signalling pathways (IL-1, IL-6 and neutrophil-related;  
299 Table S7A). These features may be consistent with an aberrant immune response including a  
300 lack of activation of regulatory and immune-suppressive pathways. T-cell exhaustion  
301 consistent with upregulation of PD-1, CTLA-4 and LAG (Table S7C) known to be associated  
302 with severe COVID-19, was not observed.

303

304 The differential expression (DE) results also revealed that a number of SARS-CoV-2 genes  
305 were significantly upregulated (FDR<0.01) in the culture-positive versus the culture-negative  
306 group including *nucleocapsid phosphoprotein* (log<sub>2</sub> FC=8.4) and *ORF3a* (log<sub>2</sub> FC=5.5) while  
307 the *surface/spike glycoprotein* encoding gene had a log<sub>2</sub> FC of 5.3 and an FDR of 0.067  
308 (Table S6). A visual inspection of the mapped SARS-CoV-2 reads revealed that those that  
309 mapped to the 5' end of the genes were spliced with a portion mapping to the 5' leader  
310 sequence of the genome. This suggests the reads originated from sub-genomic mRNA  
311 (sgRNA) rather than genomic RNA which is consistent with the active viral replication  
312 observed in the culture-positive group.

313

314 Finally, we evaluated whether any of the DE genes could act as biomarkers discriminating  
315 between lung culture-positive and negative-individuals. Logistic regression predictive

316 modelling revealed that *GREMI* and *FGFBP1* were associated with a sensitivity and  
317 specificity above 90% (further details in the online supplement). Future studies are warranted  
318 to determine if these lung-based biomarkers can predict patient culture status in blood  
319 samples.

320

321

## 322 **Discussion.**

323 The widely accepted view in severe acute COVID-19 is that resolution of the initial viral  
324 replication phase in the first week after symptom onset is followed by an effector or  
325 hyperinflammatory phase in the second and third week of illness which is characterised by  
326 diffuse alveolar damage, thrombo-inflammation, and endotheliopathy (30). Indeed, the  
327 Infectious Disease Society of America (IDSA) recommends the use of remdesivir for only 5  
328 days in patients with severe illness and not in mechanically ventilated patients (31). However,  
329 our results, based on post-mortem lung biopsies obtained using minimally invasive tissue  
330 sampling methods (MITS) shortly after death indicated that, in contradistinction to the URT  
331 where replication often ceases within ~8 days from symptom onset, in the human lung virus is  
332 culturable in ~40% of mechanically ventilated patients until death (median of 15 days and up  
333 to 4 weeks after symptom onset; see Figure 1 for the study overview). The culture-positive  
334 group in the Delta cohort had accelerated death and a higher proportion of secondary bacterial  
335 infection in the lung compared to the culture-negative group. Nasopharyngeal SARS-CoV-2  
336 viral load (based on Ct value) neither at admission nor at death, was predictive of lung  
337 culture-positivity. SARS-CoV-2 culture-positivity in the lung of decedents was associated  
338 with attenuated pulmonary T-cell immunity and an exaggerated pro-inflammatory phenotype.  
339 Importantly, this was concurrent with, rather than sequential to the viral replication or viral  
340 culture-positive phase.

341 These findings challenge the traditional paradigm of an initial viral replicative phase in the  
342 first week of severe illness sequentially followed by an effector or inflammatory phase (30).  
343 Our data suggest that in ~40% of ventilated patients, viral replication persisted until death (i.e.  
344 3<sup>rd</sup> and 4<sup>th</sup> week of illness and a median of 15 days after symptom onset) compared to ~2 to  
345 ~8 days in the URT as outlined in several studies including a live virus human challenge  
346 study (11, 14-24). One outlier study reported culturing virus from the URT for up to 3 weeks  
347 after symptom onset (32). However, a large proportion of patients were  
348 immunocompromised, samples at diagnosis and follow-up were combined (skewing the  
349 results), a high proportion of participants were healthcare workers (re-infection may have  
350 been a confounder), and as the authors suggested a limitation was that the Vero cell line used  
351 was overtly permissive to infection compared to the human lung carcinoma cell line, H1299  
352 ACE2, which is a biologically representative cell line (and one that we used). Another recent  
353 study showed that infectious virus production peaked in the human lung within 2 days, but  
354 this model used *ex vivo* agarose infused devascularised and explanted human lung slices,  
355 which are not representative of what is occurring in freshly harvested human lung (33). The  
356 culture-based findings in the afore-mentioned studies must be explicitly distinguished from  
357 studies that detected residual free viral genomic RNA (but not replicating virus) embedded in  
358 the respiratory tract tissue of patients that had severe disease for an extended period of time  
359 (13, 34, 35). Indeed, SARS-CoV-2 RNAs have been detected in patient tissue many months  
360 after recovery from acute infection (36-38). It was initially suggested that sgRNA (sub-  
361 genomic RNA; small strands of reversely transcribed RNA) could be used as a proxy to infer  
362 viral replication. However, several recent studies have indicated that it has poor predictive  
363 value as a proxy for viral replication (39, 40). Indeed, Stein et al (13) detected sgRNA in  
364 multiple post-mortem organ biopsies, including the brain, several months after symptom  
365 onset. Thus, the data presented in this manuscript is the first to do so conclusively and

366 comprehensively using viral culture from lung tissue (the gold standard to detect viral  
367 replication) beyond two weeks after symptom onset.

368

369 We demonstrated active viral replication in the lungs of acutely ill ventilated patients for up to  
370 ~4 weeks after symptom onset. This challenges the current practice of using antivirals like  
371 remdesivir for only 5 days and suggests that a longer duration of treatment may be required in  
372 critically ill patients. Furthermore, antivirals like remdesivir are not recommended for use by  
373 IDSA in mechanically ventilated patients (conditional recommendation) as they felt that such  
374 patients (often in the third week of their illness) are no longer in the viral replicative phase,  
375 and published controlled trial data showed no mortality benefit of remdesivir in such patients  
376 (31, 41). However, these studies demonstrated a group effect, and the analyses did not adjust  
377 for disease severity or the time from symptom onset to death in mechanically ventilated  
378 patients (42). Our data suggest that a significant number of patients may likely benefit from  
379 antivirals during mechanical ventilation. Indeed, several observational studies have found a  
380 survival benefit using remdesivir in mechanically ventilated patients, but this requires further  
381 clarification in appropriate trials (42-44). In a multivariate analysis we found no association  
382 between steroid usage and lung viral culture positivity - in fact, steroid usage was lower in the  
383 viral culture-positive group and often culture positivity persisted beyond the 10 days of  
384 steroid usage.

385

386 The transcriptomic data suggested that, in a significant number of patients, the  
387 hyperinflammatory and viral replication phase occur concurrently in the 3<sup>rd</sup> and 4<sup>th</sup> week of  
388 illness, in contradistinction to the widely held view that these are sequential phases. Antiviral  
389 and selective proinflammatory responses were over-represented in the SARS-CoV-2 culture-  
390 positive compared with the culture-negative decedents, and we did not detect attenuated type



391 1 interferon responses at the site of disease compared with other reports (45-49). Three prior  
392 studies (one that enrolled 5 COVID-19 patients) evaluated transcriptomic lung responses in  
393 patients with severe COVID-19 versus healthy controls (45, 46, 50). These first level studies  
394 logically attempted to address the significance of transcriptomic changes specific to COVID-  
395 19 by using healthy controls or non-diseased parts of the lung from lung cancer patients.  
396 However, we specifically sought to compare culture-positive versus culture-negative groups  
397 (hitherto not undertaken) to dissect out pathways that facilitate permissiveness to ongoing  
398 viral replication.

399

400 We identified two lung-based biomarkers (*GREM1* and *FGFBP1*) that could predict culture-  
401 positivity. Although these are lung-specific biomarkers, this preliminary analysis in a limited  
402 number of samples suggests that in the future, RT-PCR of tracheal aspirates or blood (if they  
403 are concordant with lung findings), could potentially serve as biomarkers to identify and  
404 direct appropriate treatment protocols to culture-positive persons but further investigation is  
405 needed.

406

407 There are several limitations to our findings. Firstly, our findings are relevant to acute severe  
408 COVID-19 ARDS/pneumonia requiring mechanical ventilation and may not be applicable to  
409 milder forms of disease seen in hospitalised patients or chronic infection seen in  
410 immunocompromised patients. Secondly, we only studied patients with the Beta and Delta  
411 variants as these were the predominant variant at the time of the study. However, Omicron  
412 has also been associated with severe disease in several settings including the surge of severe  
413 COVID-19 unfolding in China. Thirdly, we did not study a control group comprising severe  
414 ARDS due to other causes because our express aim was to investigate the presence and  
415 duration of viral replication in the LRT in severe COVID-19 disease. Fourth, the sample size

416 limited our ability to make conclusions about several aspects. However, the highly resource  
417 intensive and demanding nature of the study limited our ability to recruit higher numbers of  
418 participants. Fifthly, it could be suggested that there may have been sampling error and  
419 variability of the viral culture assay. However, the reproducibility of the viral culture  
420 technique using 6 samples across 2 separate runs had a low standard error, which was  
421 indicative of high reproducibility. Finally, the transcriptional signature and flow cytometric  
422 findings may have been affected by post-death sampling, but several detailed studies have  
423 shown (51) that most protein and RNA species are preserved and stable for several hours after  
424 death. Given that biopsies for the transcriptional studies were taken ~2 hours after death, we  
425 feel they are broadly representative of the picture at the time of death.

426

427 In summary, our data suggest that in COVID-19 disease there is considerable heterogeneity in  
428 the frequency and duration of viral replication in the upper versus the lower respiratory tract  
429 (i.e. lungs) beyond the 2<sup>nd</sup> week of illness, and that in a significant proportion of seriously ill  
430 patients, persisting viral replication occurs concurrently and may drive an exaggerated  
431 proinflammatory response (higher than in culture-negative persons), rather than sequentially  
432 as it is widely believed. These findings have potential implications for the use of antiviral  
433 therapy in seriously ill patients with COVID-19 and suggest that better biomarkers are needed  
434 to identify patient phenotypes and subsets that might benefit from concurrent anti-  
435 inflammatory and antiviral therapy.

436 **Figure legends.**

437

438 **Figure 1. Study overview including SARS-CoV-2 PCR-positive ambulatory controls (A)**

439 **and mechanically ventilated decedents (B) recruited during the Beta and Delta waves.**

440 Nasopharyngeal (NP) swabs from ambulatory COVID-19 controls were obtained

441 approximately 5 days after symptom onset (diagnosis), and then at 12- and 19-days post

442 symptom onset. Minimally invasive tissue samples (MITS) and NP swabs were retrieved

443 from decedents shortly after death.

444

445 **Figure 2. Active replicating virus was recovered from the lungs of over one third of**

446 **decedents (16/42). (A)** Proportion of lung biopsy samples that were culture-positive from the

447 decedents. **(B)** Proportion of ambulatory patient and decedent NP swab samples that were

448 culture-positive. **(C)** PCR positivity of organs of lung culture-positive decedents from the

449 Delta cohort. NP= nasopharyngeal.

450

451 **Figure 3. The phenotype of replicating viral persistence, compared to the culture-**

452 **negative participants, was associated with accelerated death and a higher frequency of**

453 **bacterial bronchopneumonia in the Delta but not the Beta group. (A)** The days from

454 symptom onset to death for the culture-negative (-ve; green) and culture-positive (+ve; red)

455 groups for both groups combined, and for the Beta **(B)** and Delta **(C)** groups alone. Proportion

456 of samples/participants with a secondary bacterial infection in culture-negative and culture-

457 positive decedents overall i.e. the combined groups (Beta and Delta) **(D)**, Beta group only **(E)**,

458 and Delta group only **(F)**. **(G)** PCR cycle threshold (Ct) value at the time of death or at

459 admission could not discriminate or predict lung culture status. The nasopharyngeal swab

460 PCR Ct values at admission or death were missing for some participants because they were

461 either diagnostically confirmed by antigen testing or the Ct value was not recorded. Due to the  
462 nature of the pandemic and the burden of the disease on the healthcare infrastructure at the  
463 time, Ct values at peak periods were not recorded. We have conducted sensitivity and  
464 imputation analyses indicating that these missing data points are redundant. The  
465 nasopharyngeal swab PCR Ct values at admission or death were missing for some participants  
466 because they were either diagnostically confirmed by antigen testing or the Ct value was not  
467 recorded. Due to the nature of the pandemic and the burden of the disease on the healthcare  
468 infrastructure at the time, Ct values at peak periods were not recorded. We have conducted  
469 sensitivity and imputation analyses indicating that these missing data points are redundant.

470

471 **Figure 4. A higher proportion of T-cells, macrophages and pneumonocytes infiltrate**  
472 **into the lung of the culture-negative versus culture-positive decedents in the Delta**  
473 **group. (A)** More CD3+ and CD8+ T-cells infiltrate into the alveoli and interstitial space of  
474 the lung culture-negative versus culture-positive group in the Delta decedents as assessed by  
475 immunohistochemistry. **(B)** Representative images (immunohistochemistry) showing  
476 increased T-cell infiltration into interstitial space (blue arrow) in the lung culture-negative  
477 versus the culture-positives in the Delta cohort. Histopathology findings **(C)** and  
478 representative images **(D)** associated with diffuse alveolar damage and microvascular  
479 thrombosis in the Delta decedents. The black arrows indicate key histopathological features.

480

481 **Figure 5. The transcriptomic analysis revealed that the culture-positive group, in**  
482 **comparison to the culture-negative group, had enrichment of activated pathways**  
483 **associated with inflammation, innate immunity, responses to cytokines, and responses to**  
484 **virus/ bacterial stimuli in the Delta descendants.** Dot plot illustrating the significantly  
485 activated and suppressed pathways along with the gene count and ratio for each pathway **(A)**,

486 enrichment map illustrating the significantly activated and suppressed pathways along with  
487 the gene count and ratio for each pathway (**B**) and cnetplot similarly illustrating the overlap of  
488 genes and their fold changes for selected activated pathways (**C**).

489

490

#### 491 **Contributions**

492 K.D, MT, S.J, A.P, A.E, M.D, M.N and S.M conceived and designed experiments. K.D, A.E,  
493 S.O, L.K, T.P, A.S, I.J, J.P, D.T, D.F, M.M, M.N and S.M arranged medical ethical approval,  
494 recruitment of study participants and collection of study material. MT, SJ, A.P, L.W, A.K,  
495 S.M, K.P, R.R, R.K, R.M, C.M, J.B, R.L, M.D, C vdM, A.R, M.H, V.B, S. M, C.W, and R.J  
496 performed the experiments. M.T, S.J, A.P and M.D set up experimental assays. A.S provided  
497 the cell line. K.D, M.T, S.J, A.P, L.W, A.K, L.S, S.M, K.P, R.R, R.L, M.H, V.B, S.M, R.J,  
498 and N.M analysed and interpreted data. K.D, M.T, L.S, and S.M wrote the manuscript with  
499 input from all listed authors.

500

#### 501 **Declaration of interests**

502 The authors have no competing interests.

503

#### 504 **Acknowledgments**

505 The authors would like to thank Arnold-Day C, Crowther M, Fernandes N, and Mitchell L  
506 from the Division of Critical Care, Department of Anaesthesia and Perioperative Medicine,  
507 University of Cape Town, South Africa for identifying and referring potential patients into the  
508 study.

509 The study was funded by the Bill & Melinda Gates Foundation (grant number INV-017282)

510 and the South African Medical Research Council (grant number SHIP NCD 96756) with

511 partial support from the Department of Science and Technology and National Research  
512 Foundation: South African Research Chair Initiative in Vaccine Preventable Diseases. The  
513 KD lab acknowledges funding from the SA MRC (RFA-EMU-02-2017), EDCTP (TMA-  
514 2015SF-1043, TMA-1051-TESAIII, TMA-CDF2015), UK Medical Research Council  
515 (MR/S03563X/1), NIH (CRDF-OISE-16-62105) and the Wellcome Trust (MR/S027777/1).  
516 This work was co-funded by The Wellcome Centre for Infectious Diseases Research in Africa  
517 is supported by core funding from the Wellcome Trust (230135/Z/16/Z) and the European  
518 Union’s Horizon Europe Research and Innovation Actions (101046041) for genomic  
519 surveillance.

520

521 The authors would like to thank the families of the deceased who gave us permission to  
522 conduct the study, which may advance our understanding of SARS-CoV-2 pathogenesis to  
523 inform future clinical management of respiratory pathogen pandemics.

524

525

526

527

528

529

530

531

532

533

534

535

536 **References.**

- 537 1. Davies MA, Morden E, Rosseau P, Arendse J, Bam JL, Boloko L, Cloete K, Cohen C, Chetty N,  
538 Dane P, Heekes A, Hsiao NY, Hunter M, Hussey H, Jacobs T, Jassat W, Kariem S, Kassanjee  
539 R, Laenen I, Roux SL, Lessells R, Mahomed H, Maughan D, Meintjes G, Mendelson M,  
540 Mnguni A, Moodley M, Murie K, Naude J, Ntusi NAB, Paleker M, Parker A, Pienaar D,  
541 Preiser W, Prozesky H, Raubenheimer P, Rossouw L, Schrueder N, Smith B, Smith M,  
542 Solomon W, Symons G, Taljaard J, Wasserman S, Wilkinson RJ, Wolmarans M, Wolter N,  
543 Boule A. Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven  
544 by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape  
545 Province, South Africa. *Int J Infect Dis* 2022; 127: 63-68.
- 546 2. Johns Hopkins University Center for Systems Science and Engineering. 2022. Available at:  
547 <https://coronavirus.jhu.edu/map.html>.
- 548 3. Cai J, Deng X, Yang J, Sun K, Liu H, Chen Z, Peng C, Chen X, Wu Q, Zou J, Sun R, Zheng W,  
549 Zhao Z, Lu W, Liang Y, Zhou X, Ajelli M, Yu H. Modeling transmission of SARS-CoV-2  
550 Omicron in China. *Nat Med* 2022; 28: 1468-1475.
- 551 4. Chen X, Yan X, Sun K, Zheng N, Sun R, Zhou J, Deng X, Zhuang T, Cai J, Zhang J, Ajelli M, Yu  
552 H. Estimation of disease burden and clinical severity of COVID-19 caused by Omicron BA.2  
553 in Shanghai, February-June 2022. *Emerg Microbes Infect* 2022; 11: 2800-2807.
- 554 5. Colnago M, Benvenuto GA, Casaca W, Negri RG, Fernandes EG, Cuminato JA. Risk factors  
555 associated with mortality in hospitalized patients with COVID-19 during the Omicron wave in  
556 Brazil. *Bioeng* 2022; 9.
- 557 6. Gautret P, Hoang VT, Jimeno MT, Lagier JC, Rossi P, Fournier PE, Colson P, Raoult D. The  
558 severity of the first 207 infections with the SARS-CoV-2 Omicron BA.2 variant, in Marseille,  
559 France, December 2021-February 2022. *J Med Virol* 2022; 94: 3494-3497.
- 560 7. Jassat W, Mudara C, Ozougwu L, Tempia S, Blumberg L, Davies MA, Pillay Y, Carter T,  
561 Morewane R, Wolmarans M, von Gottberg A, Bhiman JN, Walaza S, Cohen C, group Da.  
562 Difference in mortality among individuals admitted to hospital with COVID-19 during the  
563 first and second waves in South Africa: a cohort study. *Lancet Glob Health* 2021; 9: e1216-  
564 e1225.
- 565 8. Maruotti A, Ciccozzi M, Jona-Lasinio G. COVID-19-induced excess mortality in Italy during the  
566 Omicron wave. *IJID Reg* 2022; 4: 85-87.
- 567 9. Maslo C MA, Laubscher A, Toubkin M, Sitharam L, Feldman C, Richards GA. COVID-19: A  
568 comparative study of severity of patients hospitalized during the first and the second wave in  
569 South Africa. *MedRxiv* 2021.
- 570 10. Ward IL, Bermingham C, Ayoubkhani D, Gethings OJ, Pouwels KB, Yates T, Khunti K,  
571 Hippisley-Cox J, Banerjee A, Walker AS, Nafilyan V. Risk of covid-19 related deaths for  
572 SARS-CoV-2 Omicron (B.1.1.529) compared with Delta (B.1.617.2): retrospective cohort  
573 study. *BMJ* 2022; 378: e070695.
- 574 11. Fontana LM, Villamagna AH, Sikka MK, McGregor JC. Understanding viral shedding of severe  
575 acute respiratory coronavirus virus 2 (SARS-CoV-2): Review of current literature. *Infect  
576 Control Hosp Epidemiol* 2021; 42: 659-668.
- 577 12. Ramos-Rincon JM, Herrera-Garcia C, Silva-Ortega S, Portilla-Tamarit J, Alenda C, Jaime-  
578 Sanchez FA, Arenas-Jimenez J, Fornes-Riera FE, Scholz A, Escribano I, Pedrero-Castillo V,  
579 Munoz-Miguelsanz C, Orts-Llinares P, Marti-Pastor A, Amo-Lozano A, Garcia-Sevila R,  
580 Ribes-Mengual I, Moreno-Perez O, Concepcion-Aramendia L, Merino E, Sanchez-Martinez  
581 R, Aranda I. Pathological findings associated with SARS-CoV-2 on postmortem core  
582 biopsies: correlation with clinical presentation and disease course. *Front Med* 2022; 9:  
583 874307.
- 584 13. Stein SR, Ramelli SC, Grazioli A, Chung JY, Singh M, Yinda CK, Winkler CW, Sun J, Dickey  
585 JM, Ylaya K, Ko SH, Platt AP, Burbelo PD, Quezado M, Pittaluga S, Purcell M, Munster VJ,  
586 Belinky F, Ramos-Benitez MJ, Boritz EA, Lach IA, Herr DL, Rabin J, Saharia KK, Madathil  
587 RJ, Tabatabai A, Soherwardi S, McCurdy MT, Consortium NC-A, Peterson KE, Cohen JI, de  
588 Wit E, Vannella KM, Hewitt SM, Kleiner DE, Chertow DS. SARS-CoV-2 infection and  
589 persistence in the human body and brain at autopsy. *Nature* 2022; 612: 758-763.




- 590 14. Basile K, McPhie K, Carter I, Alderson S, Rahman H, Donovan L, Kumar S, Tran T, Ko D,  
591 Sivaruban T, Ngo C, Toi C, O'Sullivan MV, Sintchenko V, Chen SC, Maddocks S, Dwyer  
592 DE, Kok J. Cell-based culture informs infectivity and safe de-isolation assessments in patients  
593 with coronavirus disease 2019. *Clin Infect Dis* 2021; 73: e2952-e2959.
- 594 15. Berengua C, Lopez M, Esteban M, Marin P, Ramos P, Cuerpo MD, Gich I, Navarro F, Miro E,  
595 Rabella N. Viral culture and immunofluorescence for the detection of SARS-CoV-2  
596 infectivity in RT-PCR positive respiratory samples. *J Clin Virol* 2022; 152: 105167.
- 597 16. Bullard J, Dust K, Funk D, Strong JE, Alexander D, Garnett L, Boodman C, Bello A, Hedley A,  
598 Schiffman Z, Doan K, Bastien N, Li Y, Van Caesele PG, Poliquin G. Predicting infectious  
599 severe acute respiratory syndrome coronavirus 2 from diagnostic samples. *Clin Infect Dis*  
600 2020; 71: 2663-2666.
- 601 17. Lan L, Xu D, Ye G, Xia C, Wang S, Li Y, Xu H. Positive RT-PCR test results in patients  
602 recovered from COVID-19. *JAMA* 2020; 323: 1502-1503.
- 603 18. Ling Y, Xu SB, Lin YX, Tian D, Zhu ZQ, Dai FH, Wu F, Song ZG, Huang W, Chen J, Hu BJ,  
604 Wang S, Mao EQ, Zhu L, Zhang WH, Lu HZ. Persistence and clearance of viral RNA in 2019  
605 novel coronavirus disease rehabilitation patients. *Chin Med J* 2020; 133: 1039-1043.
- 606 19. Santos Bravo M, Berengua C, Marin P, Esteban M, Rodriguez C, Del Cuerpo M, Miro E, Cuesta  
607 G, Mosquera M, Sanchez-Palomino S, Vila J, Rabella N, Marcos MA. Viral culture confirmed  
608 SARS-CoV-2 subgenomic RNA value as a good surrogate marker of infectivity. *J Clin*  
609 *Microbiol* 2022; 60: e0160921.
- 610 20. Singanayagam A, Patel M, Charlett A, Lopez Bernal J, Saliba V, Ellis J, Ladhani S, Zambon M,  
611 Gopal R. Duration of infectiousness and correlation with RT-PCR cycle threshold values in  
612 cases of COVID-19, England, January to May 2020. *Euro Surveill* 2020; 25.
- 613 21. van Kampen JJA, van de Vijver D, Fraaij PLA, Haagmans BL, Lamers MM, Okba N, van den  
614 Akker JPC, Endeman H, Gommers D, Cornelissen JJ, Hoek RAS, van der Eerden MM,  
615 Hesselink DA, Metselaar HJ, Verbon A, de Steenwinkel JEM, Aron GI, van Gorp ECM, van  
616 Boheemen S, Voermans JC, Boucher CAB, Molenkamp R, Koopmans MPG, Geurtsvankessel  
617 C, van der Eijk AA. Duration and key determinants of infectious virus shedding in  
618 hospitalized patients with coronavirus disease-2019 (COVID-19). *Nat Commun* 2021; 12:  
619 267.
- 620 22. Wolfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Muller MA, Niemeyer D, Jones TC,  
621 Vollmar P, Rothe C, Hoelscher M, Bleicker T, Brunink S, Schneider J, Ehmann R,  
622 Zwirgmaier K, Drosten C, Wendtner C. Virological assessment of hospitalized patients with  
623 COVID-2019. *Nature* 2020; 581: 465-469.
- 624 23. Young BE, Ong SWX, Ng LFP, Anderson DE, Chia WN, Chia PY, Ang LW, Mak TM,  
625 Kalimuddin S, Chai LYA, Pada S, Tan SY, Sun L, Parthasarathy P, Fong SW, Chan YH, Tan  
626 CW, Lee B, Rotzschke O, Ding Y, Tambyah P, Low JGH, Cui L, Barkham T, Lin RTP, Leo  
627 YS, Renia L, Wang LF, Lye DC, Singapore Novel Coronavirus Outbreak Research T. Viral  
628 dynamics and immune correlates of coronavirus disease 2019 (COVID-19) severity. *Clin*  
629 *Infect Dis* 2021; 73: e2932-e2942.
- 630 24. Killingley B, Mann AJ, Kalinova M, Boyers A, Goonawardane N, Zhou J, Lindsell K, Hare SS,  
631 Brown J, Frise R, Smith E, Hopkins C, Noulin N, Londt B, Wilkinson T, Harden S, McShane  
632 H, Baillet M, Gilbert A, Jacobs M, Charman C, Mande P, Nguyen-Van-Tam JS, Semple MG,  
633 Read RC, Ferguson NM, Openshaw PJ, Rapeport G, Barclay WS, Catchpole AP, Chiu C.  
634 Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults.  
635 *Nat Med* 2022; 28: 1031-1041.
- 636 25. Suvarna SK, Layton C, Bancroft JD. *Banforde's theory and practice of histology techniques* (8<sup>th</sup>  
637 edition. Elsevier 2019.
- 638 26. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras  
639 TR. STAR): ultrafast universal RNA-seq aligner. *Bioinformatics* 2013; 29: 15-21.
- 640 27. Howe KL, Achuthan P, Allen J, Allen J, Alvarez-Jarreta J, Amode MR, Armean IM, Azov AG,  
641 Bennett R, Bhai J, Billis K, Boddu S, Charkhchi M, Cummins C, Da Rin Fioretto L, Davidson  
642 C, Dodiya K, El Houdaigui B, Fatima R, Gall A, Garcia Giron C, Grego T, Guizarro-Clarke C,  
643 Haggerty L, Hemrom A, Hourlier T, Izuogu OG, Juettemann T, Kaikala V, Kay M, Lavidas I,  
644 Le T, Lemos D, Gonzalez Martinez J, Marugan JC, Maurel T, McMahan AC, Mohanan S,




- 645 Moore B, Muffato M, Oheh DN, Paraschas D, Parker A, Parton A, Prosovetskaia I, Sakthivel  
646 MP, Salam AIA, Schmitt BM, Schuilenburg H, Sheppard D, Steed E, Szpak M, Szuba M,  
647 Taylor K, Thormann A, Threadgold G, Walts B, Winterbottom A, Chakiachvili M, Chaubal  
648 A, De Silva N, Flint B, Frankish A, Hunt SE, GR II, Langridge N, Loveland JE, Martin FJ,  
649 Mudge JM, Morales J, Perry E, Ruffier M, Tate J, Thybert D, Trevanion SJ, Cunningham F,  
650 Yates AD, Zerbino DR, Flicek P. *Ensembl* 2021. *Nucleic Acids Res* 2021; 49: D884-D891.
- 651 28. Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, Feng T, Zhou L, Tang W, Zhan L, Fu X, Liu S, Bo X,  
652 Yu G. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. *Innov* 2021;  
653 2: 100141.
- 654 29. Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 cytokine storm; what  
655 we know so far. *Front Immunol* 2020; 11: 1446.
- 656 30. Merad M, Blish CA, Sallusto F, Iwasaki A. The immunology and immunopathology of COVID-  
657 19. *Science* 2022; 375: 1122-1127.
- 658 31. Bhimraj A MR, Shumaker AH, Baden L, Cheng VC, Edwards KM, Gallagher JC, Gandhi RT,  
659 Muller WJ, Nakamura MM, O'Horo JC, Shafer RW, Shoham S, Murad MH, Mustafa RA,  
660 Sultan S, Falck-Ytte Y. IDSA Guidelines on the Treatment and Management of Patients with  
661 COVID-19. 2022. Available at: [https://www.idsociety.org/practice-guideline/covid-19-](https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/#Recommendations15-17:Remdesivir)  
662 [guideline-treatment-and-management/#Recommendations15-17:Remdesivir](https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/#Recommendations15-17:Remdesivir).
- 663 32. Folgueira MD, Luczkowiak J, Lasala F, Perez-Rivilla A, Delgado R. Prolonged SARS-CoV-2 cell  
664 culture replication in respiratory samples from patients with severe COVID-19. *Clin*  
665 *Microbiol Infect* 2021; 27: 886-891.
- 666 33. Pechous RD, Malaviarachchi PA, Banerjee SK, Byrum SD, Alkam DH, Ghaffarieh A, Kurten RC,  
667 Kennedy JL, Xuming Z. An ex vivo human precision-cut lung slice platform provides insight  
668 into SARS2 CoV-2 pathogenesis and antiviral drug efficacy. *bioRxiv* 2023.
- 669 34. Xu Q, Milanez-Almeida P, Martins AJ, Radtke AJ, Hoehn KB, Oguz C, Chen J, Liu C, Tang J,  
670 Grubbs G, Stein S, Ramelli S, Kabat J, Behzadpour H, Karkanitsa M, Spathies J, Kalish H,  
671 Kardava L, Kirby M, Cheung F, Preite S, Duncker PC, Kitakule MM, Romero N, Preciado D,  
672 Gitman L, Koroleva G, Smith G, Shaffer A, McBain IT, McGuire PJ, Pittaluga S, Germain  
673 RN, Apps R, Schwartz DM, Sadtler K, Moir S, Chertow DS, Kleinstein SH, Khurana S, Tsang  
674 JS, Mudd P, Schwartzberg PL, Manthiram K. Adaptive immune responses to SARS-CoV-2  
675 persist in the pharyngeal lymphoid tissue of children. *Nat Immunol* 2023; 24: 186-199.
- 676 35. Zollner A, Koch R, Jukic A, Pfister A, Meyer M, Rossler A, Kimpel J, Adolph TE, Tilg H.  
677 Postacute COVID-19 is characterized by gut viral antigen persistence in inflammatory bowel  
678 diseases. *Gastroenterology* 2022; 163: 495-506 e498.
- 679 36. Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, Solomon IH, Kuo HH, Boucau J,  
680 Bowman K, Adhikari UD, Winkler ML, Mueller AA, Hsu TY, Desjardins M, Baden LR,  
681 Chan BT, Walker BD, Lichterfeld M, Brigl M, Kwon DS, Kanjilal S, Richardson ET, Jonsson  
682 AH, Alter G, Barczak AK, Hanage WP, Yu XG, Gaiha GD, Seaman MS, Cernadas M, Li JZ.  
683 Persistence and evolution of SARS-CoV-2 in an immunocompromised host. *NEJM* 2020; 383:  
684 2291-2293.
- 685 37. Griffin I, Woodworth KR, Galang RR, Burkel VK, Neelam V, Siebman S, Barton J, Manning SE,  
686 Aveni K, Longcore ND, Harvey EM, Ngo V, Mbotha D, Chicchelly S, Lush M, Eckert V,  
687 Dzimiria P, Sokale A, Valencia-Prado M, Azziz-Baumgartner E, MacNeil A, Gilboa SM, Tong  
688 VT. Recurrent SARS-CoV-2 RNA detection after COVID-19 illness onset during pregnancy.  
689 *Emerg Infect Dis* 2022; 28: 873-876.
- 690 38. Rodriguez-Grande C, Alcalá L, Estevez A, Sola-Campoy PJ, Buenestado-Serrano S, Martinez-  
691 Laperche C, Manuel de la Cueva V, Alonso R, Andres-Zayas C, Adan-Jimenez J, Losada C,  
692 Rico-Luna C, Comas I, Gonzalez-Candelas F, Catalan P, Munoz P, Perez-Lago L, Garcia de  
693 Viedma D, Gregorio Marañon Microbiology IDCSG. Systematic genomic and clinical  
694 analysis of severe acute respiratory syndrome coronavirus 2 reinfections and recurrences  
695 involving the same strain. *Emerg Infect Dis* 2022; 28: 85-94.
- 696 39. Alexandersen S, Chamings A, Bhatta TR. SARS-CoV-2 genomic and subgenomic RNAs in  
697 diagnostic samples are not an indicator of active replication. *Nat Commun* 2020; 11: 6059.
- 698 40. Hwang HS, Lo CM, Murphy M, Grudda T, Gallagher N, Luo CH, Robinson ML, Mirza A, Conte  
699 M, Conte A, Zhou R, Vergara C, Brooke CB, Pekosz A, Mostafa HH, Manabe YC, Thio CL,

- 700 Balagopal A. Characterizing SARS-CoV-2 Transcription of Subgenomic and Genomic RNAs  
701 During Early Human Infection Using Multiplexed Droplet Digital Polymerase Chain  
702 Reaction. *J Infect Dis* 2023; 227: 981-992.
- 703 41. Consortium WHOST. Remdesivir and three other drugs for hospitalised patients with COVID-19:  
704 final results of the WHO Solidarity randomised trial and updated meta-analyses. *Lancet* 2022;  
705 399: 1941-1953.
- 706 42. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY,  
707 Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L,  
708 Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh  
709 MD, Ruiz-Palacios GM, Benfield T, Fatkenheuer G, Kortepeter MG, Atmar RL, Creech CB,  
710 Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M,  
711 Osinusi A, Nayak S, Lane HC, Members A-SG. Remdesivir for the treatment of Covid-19 -  
712 final report. *NEJM* 2020; 383: 1813-1826.
- 713 43. Lapidula G, Bernasconi DP, Bellani G, Soria A, Rona R, Bombino M, Avalli L, Rondelli E,  
714 Cortinovis B, Colombo E, Valsecchi MG, Migliorino GM, Bonfanti P, Foti G, Remdesivir-Ria  
715 Study G. Remdesivir use in patients requiring mechanical ventilation due to COVID-19. *Open*  
716 *Forum Infect Dis* 2020; 7: ofaa481.
- 717 44. Pasquini Z, Montalti R, Temperoni C, Canovari B, Mancini M, Tempesta M, Pimpini D, Zallocco  
718 N, Barchiesi F. Effectiveness of remdesivir in patients with COVID-19 under mechanical  
719 ventilation in an Italian ICU. *J Antimicrob Chemother* 2020; 75: 3359-3365.
- 720 45. Budhraj A, Basu A, Gheware A, Abhilash D, Rajagopala S, Pakala S, Sumit M, Ray A,  
721 Subramaniam A, Mathur P, Nambirajan A, Kumar S, Gupta R, Wig N, Trikha A, Guleria R,  
722 Sarkar C, Gupta I, Jain D. Molecular signature of postmortem lung tissue from COVID-19  
723 patients suggests distinct trajectories driving mortality. *Dis Model Mech* 2022; 15.
- 724 46. Melms JC, Biermann J, Huang H, Wang Y, Nair A, Tagore S, Katsyv I, Rendeiro AF, Amin AD,  
725 Schapiro D, Frangieh CJ, Luoma AM, Filliol A, Fang Y, Ravichandran H, Clausi MG, Alba  
726 GA, Rogava M, Chen SW, Ho P, Montoro DT, Kornberg AE, Han AS, Bakhoun MF,  
727 Anandasabapathy N, Suarez-Farinas M, Bakhoun SF, Borczuk A, Guo XV,  
728 Lefkowitz JH, Marboe C, Lagana SM, Del Portillo A, Tsai EJ, Zorn E, Markowitz GS,  
729 Schwabe RF, Schwartz RE, Elemento O, Saqi A, Hibshoosh H, Que J, Izar B. A molecular  
730 single-cell lung atlas of lethal COVID-19. *Nature* 2021; 595: 114-119.
- 731 47. Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity,  
732 inflammation and intervention. *Nat Rev Immunol* 2020; 20: 363-374.
- 733 48. van de Veerdonk FL, Giamarellos-Bourboulis E, Pickkers P, Derde L, Leavis H, van Crevel R,  
734 Engel JJ, Wiersinga WJ, Vlaar APJ, Shankar-Hari M, van der Poll T, Bonten M, Angus DC,  
735 van der Meer JWM, Netea MG. A guide to immunotherapy for COVID-19. *Nat Med* 2022;  
736 28: 39-50.
- 737 49. Wang EY, Mao T, Klein J, Dai Y, Huck JD, Jaycox JR, Liu F, Zhou T, Israelow B, Wong P,  
738 Coppi A, Lucas C, Silva J, Oh JE, Song E, Perotti ES, Zheng NS, Fischer S, Campbell M,  
739 Fournier JB, Wyllie AL, Vogels CBF, Ott IM, Kalinich CC, Petrone ME, Watkins AE, Yale  
740 IT, Dela Cruz C, Farhadian SF, Schulz WL, Ma S, Grubaugh ND, Ko AI, Iwasaki A, Ring  
741 AM. Diverse functional autoantibodies in patients with COVID-19. *Nature* 2021; 595: 283-  
742 288.
- 743 50. Wang S, Yao X, Ma S, Ping Y, Fan Y, Sun S, He Z, Shi Y, Sun L, Xiao S, Song M, Cai J, Li J,  
744 Tang R, Zhao L, Wang C, Wang Q, Zhao L, Hu H, Liu X, Sun G, Chen L, Pan G, Chen H, Li  
745 Q, Zhang P, Xu Y, Feng H, Zhao GG, Wen T, Yang Y, Huang X, Li W, Liu Z, Wang H, Wu  
746 H, Hu B, Ren Y, Zhou Q, Qu J, Zhang W, Liu GH, Bian XW. A single-cell transcriptomic  
747 landscape of the lungs of patients with COVID-19. *Nat Cell Biol* 2021; 23: 1314-1328.
- 748 51. Deinhardt-Emmer S, Wittschieber D, Sanft J, Kleemann S, Elschner S, Haupt KF, Vau V, Haring  
749 C, Rodel J, Henke A, Ehrhardt C, Bauer M, Philipp M, Gassler N, Nietzsche S, Löffler B,  
750 Mall G. Early postmortem mapping of SARS-CoV-2 RNA in patients with COVID-19 and the  
751 correlation with tissue damage. *Elife* 2021; 10.



\*The 16 decedents that were nasopharyngeal culture-positive were not the same patients that were lung culture-positive. #Immunohistochemistry, RNAseq, electron microscopy and viral culture of other organs was only performed on the Delta cohort.

**Figure 1.**



**Figure 2.**




Figure 3.

A

A greater proportion of CD3+ T-cells and CD8+ T-cells infiltrate into the alveoli and interstitial space in culture-negative compared to culture-positive individuals in the Delta decedents

Frequency of infiltration into the alveoli	Lung culture status		p value
	-ve (n=11 <sup>a</sup> )	+ve (n=7 <sup>b</sup> )	
<b>CD3+</b>			
Medium	55% (6/11)	0% (0/7)	<b>0.038</b>
High	0% (0/11)	0% (0/7)	N/A
<b>CD8+</b>			
Medium	54.5% (6/11)	0% (0/7)	<b>0.038</b>
High	0% (0/11)	0% (0/6)	N/A

CD68 (macrophage marker)


C

A greater proportion of type II pneumocytes proliferation and haemophagocytosis was observed in the alveoli of the culture-negative compared to culture-positive individuals in the Delta group

Lung histology	Lung culture status		p-value
	-ve (n=20 <sup>a</sup> )	+ve (n=13 <sup>b</sup> )	
Alveolar hyaline membranes	16/20 (80%)	8/13 (61.5%)	0.425
Microvascular thrombosis	6/20 (30%)	5/13 (38.5%)	0.714
Organising hyaline membranes	9/12 (75%)	6/7 (86%)	1
Type II pneumocytes proliferation	20/20 (100%)	10/13 (77%)	0.052
Organising pneumonia	6/20 (30%)	4/13 (31%)	1
Lung haemophagocytosis	14/20 (70%)	3/13 (23%)	<b>0.013</b>

<sup>a</sup>IHC was not performed on 5 culture-negative samples. <sup>b</sup>IHC was not performed on 1 culture-positive sample. \* Histology was not performed on all the biopsy samples. N/A = not applicable.

Representative images showing CD3+ and CD8+ T-cells infiltration into the alveoli and interstitial space of the lung in culture-negative compared to culture-positive individuals in the Delta decedents



D

Both culture-positive and culture-negative decedents present with histopathological findings typically associated with SARS-CoV-2 pneumonia




Figure 4.



The culture-positive, group compared to the culture-negative group, was associated with the enrichment of inflammatory, innate immune and enhanced SARS-CoV-2 entry pathways




Figure 5.